Havrix

Havrix is a prescription vaccine that contains an inactivated hepatitis A virus and the adjuvant algeldrate. It is supplied in an intramuscular injectable form for use in the European market. The product is designed to stimulate the immune system to produce protective antibodies against hepatitis A infection. Havrix is administered by a health professional according to recommended immunization schedules and is approved for individuals aged one year and older.

Havrix is indicated for the active immunization against hepatitis A virus infection in several clinical situations.

- Primary prevention of hepatitis A infection in healthy individuals. - Pre‑travel protection for persons traveling to regions where hepatitis A is endemic. - Outbreak control when hepatitis A cases are identified in a community. - Post‑exposure prophylaxis for individuals who have been exposed to hepatitis A and are not previously immunized. - Immunization of children and adolescents as part of routine vaccination programs.

The safety profile of Havrix includes both common, mild reactions and rare, more serious events.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or mild malaise.

Serious: - Severe allergic reaction (anaphylaxis) with difficulty breathing or swelling of the face. - Guillain‑Barré syndrome, a rare neurological disorder. - Persistent high fever or severe rash.

Before administering Havrix, health professionals should consider several precautionary factors to ensure safe use.

- Confirm that the individual has not previously received a hepatitis A vaccine or has documented immunity. - Defer vaccination in persons with a known severe allergy to any vaccine component, including algeldrate. - Use caution in individuals with a history of hypersensitivity reactions to previous doses of Havrix. - Assess the benefit‑risk balance for pregnant or breastfeeding women, as safety data are limited. - Monitor for signs of an allergic reaction for at least 15 minutes after injection. - Consider postponing vaccination in patients with acute moderate or severe illness. - Review immunocompromised status, as response to the vaccine may be reduced.

Havrix generally has a low potential for drug interactions, but certain substances may affect its safety or effectiveness.

Avoid: - Concurrent administration of other vaccines containing live attenuated viruses, which may interfere with immune response. - Use of immunoglobulin products or blood products containing anti‑hepatitis A antibodies within two weeks before or after vaccination.

Use with caution: - Immunosuppressive therapies (e.g., corticosteroids, chemotherapy) that may diminish antibody production. - Antipyretic or analgesic medications taken prophylactically, which could mask mild post‑vaccination symptoms. - Chronic liver disease medications, where hepatitis A infection risk is higher and vaccination timing may need adjustment.